Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion

To observe the safety of fixed dose rate gemcitabine by intravenous infusion (iv-FDR) for cancers. From January 1, 2007 to December 31, 2009, four patients who were pathologically diagnosed with advanced pancreatic or breast cancer were recruited into this study. They were treated by gemcitabine 10m...

Full description

Saved in:
Bibliographic Details
Published inAsian Pacific journal of cancer prevention : APJCP Vol. 11; no. 2; p. 553
Main Authors Yao, Cheng-Yun, Huang, Xin-En, Tang, Jin-Hai, Xu, Hong-Xia
Format Journal Article
LanguageEnglish
Published Thailand 2010
Subjects
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Dose-Response Relationship, Drug
Female
Humans
Infusions, Intravenous
Male
Middle Aged
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - pathology
Prognosis
Online AccessGet more information

Cover

More Information
Summary:To observe the safety of fixed dose rate gemcitabine by intravenous infusion (iv-FDR) for cancers. From January 1, 2007 to December 31, 2009, four patients who were pathologically diagnosed with advanced pancreatic or breast cancer were recruited into this study. They were treated by gemcitabine 10mg/m2/min iv-FDR on days 1 and 8, and combined with other chemotherapeutics, repeated every four weeks. Toxicity was determined in line with the National Cancer Institute-Common Toxicity Criteria (NCI-CTC). The main toxicity was reversible myelosuppression; other side effects included gastrointestinal toxicity and liver impairment. Cardiac or renal toxicity was not detected. The toxicity of iv-FDR gemcitabine combination chemotherapy was well tolerated, so that iv-FDR gemcitabine deserves to be further studied as a treatment option.
ISSN:2476-762X